Rocklatan has been on the market since it received FDA approval on [1] February 28, 2020 [2].
When does Rocklatan's patent expire?
The patent for Rocklatan is set to expire in 2035 [3].
What other drugs are used to treat glaucoma?
Other medications used to treat glaucoma include prostaglandin analogs like latanoprost, travoprost, and bimatoprost, as well as beta-blockers, alpha-adrenergic agonists, and carbonic anhydrase inhibitors [4].
How effective is Rocklatan compared to other glaucoma treatments?
Rocklatan is a combination medication containing netarsudil and latanoprost. Netarsudil works differently than other glaucoma medications by increasing the outflow of fluid through the trabecular meshwork, in addition to the uveoscleral pathway targeted by latanoprost [5]. Clinical studies have shown that Rocklatan can lower intraocular pressure (IOP) effectively [2].
What are the potential side effects of Rocklatan?
Common side effects of Rocklatan include conjunctival hyperemia (redness), which occurs in a significant percentage of patients, as well as keratitis, eye pain, and reduced visual acuity [2].
What is the brand name for netarsudil and latanoprost?
Rocklatan is the brand name for the combination of netarsudil and latanoprost [5].
Can generic versions of Rocklatan be developed?
The development of generic versions of Rocklatan will likely be influenced by the expiration of its patents in 2035 [3].
What is the mechanism of action for Rocklatan?
Rocklatan combines netarsudil, a Rho-kinase inhibitor, with latanoprost, a prostaglandin F2α analog [5]. Netarsudil is thought to lower intraocular pressure by increasing outflow through the trabecular meshwork pathway and decreasing episcleral venous pressure. Latanoprost increases outflow through the uveoscleral pathway [5].
Sources:
1. https://www.drugpatentwatch.com/